Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065472 | 0.80 | LMNA (0.54) | LMNAGABRR1RPS6KB1AKT1ALDH1A1 | |
| SCHEMBL19575386 | 0.77 | LMNA (0.57) | LMNAGABRR1RPS6KB1AKT1ALDH1A1 | |
| SCHEMBL4925641 | 0.76 | ALDH1A1 (0.36) | LMNAALDH1A1 | |
| SCHEMBL16516910 | 0.75 | HCAR2 (0.36) | RPS6KB1AKT1TSHRCSNK2A2CSNK2A1 | |
| SCHEMBL30002581 | 0.75 | HCAR2 (0.36) | RPS6KB1AKT1TSHRCSNK2A2CSNK2A1 | |
| SCHEMBL2884786 | 0.74 | LMNA (0.58) | LMNAALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL3433360 | 0.73 | RET (0.31) | — | |
| SCHEMBL6273818 | 0.72 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL4938648 | 0.72 | CYP1A2 (0.37) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1689338 | 0.71 | RPS6KB1 (0.39) | RPS6KB1AKT1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2708538-A1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2014-03-19 | — | — | EP | disclosed |
| EP-2411393-B1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109287-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | LMNA 2943/4885GABRR1 1337/4885RPS6KB1 2836/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | LMNA 2534/4885GABRR1 1878/4885RPS6KB1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.